| Drug Name |
Sitaxentan |
| Drug ID |
BADD_D02031 |
| Description |
Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity. |
| Indications and Usage |
Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
C02KX03 |
| DrugBank ID |
DB06268
|
| KEGG ID |
D07171
|
| MeSH ID |
C106276
|
| PubChem ID |
216235
|
| TTD Drug ID |
D0T1RG
|
| NDC Product Code |
Not Available |
| UNII |
J9QH779MEM
|
| Synonyms |
sitaxsentan | N-(4-chloro-3-methyl-5-isoxazolyl)-2-(3,4-(methylenedioxy)-6-methyl)phenylacetyl-3-thiophenesulfonamide | N-(4-chloro-3-methyl-5-isoxazolyl)-2-((4,5-(methylenedioxy)-O-toly)acetyl)-3-thiophenesulfonamide | TBC-11251 | TBC 11251 | TBC11251 |
